Federal Register / Vol. 62, No. 43 / Wednesday, March 5, 1997 / Notices 10047

the teleconference to be mailed to the

Council or its appropriate subcommittee

participants shortly after the

teleconference. Written comments may

be provided up until the time of the

meeting.

Dated: February 24, 1997.

Donald G. Barnes,

Staff Director, Science Advisory Board.

[FR Doc. 97–5309 Filed 3–4–97; 8:45 am]

BILLING CODE 6560–50–P

[PF–705; FRL–5585–6]

Bayer Corporation; Pesticide

Tolerance Petition Filing

AGENCY: Environmental Protection

Agency (EPA).

ACTION: Notice of Filing.

SUMMARY: This notice announces the

filing of a pesticide petition proposing

the establishment of a tolerance for

residues of tebuconazole in or on

grapes. This notice contains a summary

of the petition that was prepared by the

petitioner, Bayer Corporation.

DATES: Comments, identified by the

docket control number PF–705 must be

received on or before April 4, 1997.

ADDRESSES: By mail, submit written

comments to: Public Response and

Program Resources Branch, Field

Operations Division (7506C), Office of

Pesticide Programs, Environmental

Protection Agency, 401 M St., SW.,

Washington, DC 20460. In person, bring

comments to: Rm. 1132, Crystal Mall #2,

1921 Jefferson Davis Highway.,

Arlington, VA 22202.

Comments and data may also be

submitted electronically by sending

electronic mail (e-mail) to: oppdocket@epamail.epa.gov. Electronic

comments must be submitted as an

ASCII file avoiding the use of special

characters and any form of encryption.

Comments and data will also be

accepted on disks in WordPerfect 5.1

file format or ASCII file format. All

comments and data in electronic form

must be identified by the docket control

number PF–705. Electronic comments

on this notice may be filed online at

many Federal Depository Libraries.

Additional information on electronic

submissions can be found below in this

document.

Information submitted as a comment

concerning this notice may be claimed

confidential by marking any part or all

of that information as ‘‘Confidential

Business Information’’ (CBI). No CBI

should be submitted through e-mail.

Information marked as CBI will not be

disclosed except in accordance with

procedures set forth in 40 CFR part 2.

A copy of the comment that does not

contain CBI must be submitted for

inclusion in the public record.

Information not marked confidential

may be disclosed publicly by EPA

without prior notice. All written

comments will be available for public

inspection in Rm. 1132 at the address

given above from 8:30 a. m. to 4 p.m.,

Monday through Friday, excluding legal

holidays.

FOR FURTHER INFORMATION CONTACT:

Connie B. Welch, Product Manager (PM)

21, Registration Division (7505C), Office

of Pesticide Programs, Environmental

Protection Agency, 401 M St., SW.,

Washington, DC 20460. Office location,

telephone number, and e-mail address:

Rm. 227, CM #2, 1921 Jefferson Davis

Highway, Arlington, VA, (703) 305–

6226; e-mail:

welch.connie@epamail.epa.gov.

SUPPLEMENTARY INFORMATION: EPA has

received a pesticide petition (PP)

6F4669 from Bayer Corp., P.O. Box

4913, 8400 Hawthorne Road, Kansas

City, MO 64120–0013, proposing

pursuant to section 408(d) of the Federal

Food, Drug, and Cosmetic Act (FFDCA),

21 U.S.C. 346a, to amend 40 CFR

180.474 by establishing tolerances for

residues of the fungicide tebuconazole

in or on the agricultural commodity

grapes at 5.0 ppm. The proposed

analytical method for determining

residues uses gas-liquid

chromatography coupled with a

thermionic detector. EPA has

determined that the petition contains

data or information regarding the

elements set forth in section 408(d)(2);

however, EPA has not fully evaluated

the sufficiency of the submitted data at

this time or whether the data supports

granting of the petition. Additional data

may be needed before EPA rules on the

petition.

As required by section 408(d) of the

FFDCA, as recently amended by the

Food Quality Protection Act, (Pub. L.

104–170), Bayer included in the petition

a summary of the petition and

authorization for the summary to be

published in the Federal Register in a

notice of receipt of the petition. The

summary represents the views of Bayer;

EPA is in the process of evaluating the

petition. As required by section

408(d)(3) EPA is including the summary

as a part of this notice of filing. EPA

may have made minor edits to the

summary for the purpose of clarity.

I. Petition Summary

A. Residue Chemistry

1. Nature of residue. Bayer believes

the nature of the residue in plants and

animals is adequately understood. The

residue of concern is the parent

compound only, as specified in 40 CFR

180.474.

2. Analytical method. An enforcement

method for plant commodities has been

validated on various commodities. It has

undergone successful EPA validation

and has been submitted for inclusion in

PAM II. The method should be adequate

for grapes. The animal method has also

been approved as an adequate

enforcement method and will be

submitted to FDA for inclusion in PAM

II.

3. Magnitude of residue. Fifteen

separate residue trials have been

conducted and submitted to the EPA

with tebuconazole on grapes. The EPA

has determined that these data show

that residues of tebuconazole, ù-[2-(4

-Chlorophenyl)ethyl]-ù-(1,1-

dimethylethyl)-H-1,2,4-triazole-1-

ethanol, are not expected to exceed 5

ppm in grapes as a result of the

proposed use. Processing data show that

residue of tebuconazole do not

concentrate in grape juice and that a

tolerance is not required in or on

raisins. In addition, since grapes are not

normally rotated, the nature of residue

in rotational crops is not of concern.

B. Toxicological Profile

The following mammalian toxicity

studies have been conducted to support

the tolerances of tebuconazole:

1. Acute toxicity. i. Rat acute oral

study with an LD50 of >5,000

milligrams/kilogram (mg)/(kg) (male)

and 3,933 mg/kg (female).

ii. Rabbit acute dermal of LD50 of

>5,000 mg/kg.

iii. Rat acute inhalation of LC50 of

>0.371 mg/liter(l).

iv. Primary eye irritation study in the

rabbit which showed mild irritation

reversible by day 7.

v. Primary dermal irritation study

which showed no skin irritation.

vi. Primary dermal sensitization study

which showed no sensitization.

2. Genotoxicity. i. An Ames

mutagenesis study in Salmonella

showed no mutagenicity with or

without metabolic activation.

ii. A micronucleus mutagenesis assay

study in mice showed no genotoxicity.

iii. A sister chromatid exchange

mutagenesis study using CHO cells was

negative at dose levels 4 to 30

micrograms/milliliter (μg/mL) without

activation or 15 to 120 μg/mL with

activation.

iv. An unscheduled DNA synthesis

(UDS) study was negative for UDS in rat

hepatocytes.

3. Reproductive and developmental

toxicity. i. A rat oral developmental

toxicity study with a maternal no
10048 Federal Register / Vol. 62, No. 43 / Wednesday, March 5, 1997 / Notices

observed effect level (NOEL) of 30

milligrams per kilogram of body weight

per day (mg/kg bw/day) and an lowest

effect level (LEL) of 60 mg/kg bw/day

based on elevation of absolute and

relative liver weights. For

developmental toxicity, a NOEL of 30

mg/kg bw/day and an LEL of 60 mg/kg

bw/day was determined, based on

delayed ossification of thoracic, cervical

and sacral vertebrae, sternum, fore and

hind limbs and increase in

supernumerary ribs.

ii. A rabbit oral developmental

toxicity study with a maternal NOEL of

30 mg/kg bw/day and an LEL of 100 mg/

kg bw/day based on depression of body

weight gains and food consumption.

iii. A developmental NOEL of 30 mg/

kg bw/day and an LEL of 100 mg/kg bw/

day were based on increased postimplantation losses, from both early and

late resorptions and frank

malformations in eight fetuses of five

litters.

iv. A mouse oral developmental

toxicity study with a maternal NOEL of

10 mg/kg bw/day and an LEL of 20 mg/

kg bw/day based on a supplementary

study indicating reduction in hematocrit

and histological changes in liver.

v. A developmental NOEL of 10 mg/

kg bw/day and an LEL of 30 mg/kg bw/

day based on dose-dependent increases

in runts/dam at 30 and 100 mg/kg bw/

day.

vi. A mouse dermal developmental

toxicity study with a maternal NOEL of

30 mg/kg bw/day and an LEL of 60 mg/

kg bw/day based on a supplementary

study indicating increased liver

microsomal enzymes and histological

changes in liver.

vii. The NOEL for developmental

toxicity in the dermal study in the

mouse is 1,000 mg/kg bw/day, the

highest dose tested (HDT).

viii. A 2–generation rat reproduction

study with a dietary maternal NOEL of

15 mg/kg bw/day (300 ppm) and an LEL

of 50 mg/kg bw/day (1,000 ppm) based

on depressed body weights, increased

spleen hemosiderosis, and decreased

liver and kidney weights.

ix. A reproductive NOEL of 15 mg/kg

bw/day (300 ppm) and an LEL of 50 mg/

kg bw/day (1,000 ppm) were based on

neonatal birth weight depression.

4. Subchronic toxicity. i. A 28–day

feeding study in the rat with a NOEL of

30 mg/kg/day and a LEL of 100 mg/kg/

day based on changes in hematology

and clinical chemistry parameters.

ii. A 90–day rat feeding study with a

NOEL of 34.8 mg/kg bw/day (400 ppm)

and an LEL of 171.7 mg/kg bw/day

(1,600 ppm) in males, based on

decreased body weight gains and

histological changes in the adrenals. For

females, the NOEL was 10.8 mg/kg bw/

day (100 ppm) and the LEL was 46.5

mg/kg bw/day (400 ppm) based on

decreased body weights, decreased body

weight gains, and histological changes

in the adrenals.

iii. A 90–day dog-feeding study with

a NOEL of 200 ppm (73.7 mg/kg bw/day

in males and 73.4 mg/kg bw/day in

females) and an LEL of 1,000 ppm

(368.3 mg/kg bw/day in males and 351.8

mg/kg bw/day in females). The LEL was

based on decreases in mean body

weights, body weight gains, and food

consumption, and an increase in liver

N-demethylase activity.

5. Chronic toxicity. i. A 2–year rat

chronic feeding study defined a NOEL

of 7.4 mg/kg bw/day (100 ppm) and an

LEL of 22.8 mg/kg bw/day (300 ppm)

based on body weight depression,

decreased hemoglobin, hematocrit, MCV

and MCHC, and increased liver

microsomal enzymes in females.

Tebuconazole was not oncogenic at the

dose levels tested (0, 100, 300, and

1,000 ppm).

ii. A 1–year dog feeding study with a

NOEL of 1 mg/kg bw/day (40 ppm) and

an LEL of 5 mg/kg bw/day (200 ppm),

based on lenticular and corneal opacity

and hepatic toxicity in either sex (the

current Reference Dose was determined

based on this study). A subsequent 1–

year dog feeding study, using lower

doses to further define the NOEL for

tebuconazole, defines a systemic LOEL

of 150 ppm (based on adrenal effects in

both sexes) and a systemic NOEL of 100

ppm.

iii. A mouse oncogenicity study at

dietary levels of 0, 20, 60, and 80 ppm

for 21 months did not reveal any

oncogenic effect for tebuconazole at any

dose tested. Because the maximumtolerated-dose (MTD) was not reached

in this study, the study was classified as

supplementary. A follow-up mouse

study at higher doses (0, 500, and 1,500

ppm in the diet), with an MTD at 500

ppm, revealed statistically significant

incidences of hepatocellular adenomas

and carcinomas in males and

carcinomas in females. The initial and

follow-up studies, together with

supplementary data were classified as

core minimum.

6. Animal metabolism. A general rat

metabolism study at dietary levels of 2

and 20 mg/kg showed rapid elimination

from the rat in 3 days (some 99 percent

excreted by the feces and urine and

0.0304 percent in expired air). Increased

concentrations of radioactivity from the

active ingredient and metabolites were

found only in the liver. The bones and

the brain were among the tissues

showing the least amount of

radioactivity.

7. Metabolite toxicity. The residue of

concern in plants is the parent

compound, tebuconazole, only. For

animal commodities, the EPA has

determined that the tolerance

expression should include the HWG

2061 metabolite, ù-[2-(4 -Chlorophenyl)-

ethyl]-ù-[(2-hydroxy-1,1-

dimethyl)ethyl]-1H-1,2,4-triazole-1-

ethanol. An acute oral toxicity study has

been submitted to the EPA on this

metabolite. This study shows an oral

LD50 of >5,000 for female rats. This

value indicates that the HWG 2061

metabolite is relatively innocuous and

less acutely toxic than tebuconazole.

8. Endocrine effects. No special

studies investigating potential

estrogenic or endocrine effects of

tebuconazole have been conducted.

However, the standard battery of

required studies has been completed.

These studies include an evaluation of

the potential effects on reproduction

and development, and an evaluation of

the pathology of the endocrine organs

following repeated or long-term

exposure. These studies are generally

considered to be sufficient to detect any

endocrine effects but no such effects

were noted in any of the studies with

either tebuconazole or its metabolites.

9. Carcinogenicity. EPA’s

Carcinogenicity Peer Review Committee

(CPRC) has classified tebuconazole as a

Group C carcinogen (possible human

carcinogen). This classification is based

on the Agency’s ‘‘Guidelines for

Carcinogen Risk Assessment’’ published

in the Federal Register of September 24,

1986 (51 FR 33992). The Agency has

chosen to use the reference dose

calculations to estimate human dietary

risk from tebuconazole residues. The

decision supporting classification of

tebuconazole as a possible human

carcinogen (Group C) was primarily

based on the statistically significant

increase in the incidence of

hepatocellular adenomas, carcinomas,

and combined adenomas/carcinomas in

both sexes of NMRI mice both by

positive trend and pairwise comparison

at the HDT.

C. Aggregate Exposure

1. Dietary (food) exposure. For

purposes of assessing the potential

dietary exposure from food under the

proposed tolerances, Bayer has

estimated exposure based on the

Theoretical Maximum Residue

Contribution (TMRC) derived from the

previously established tolerances for

tebuconazole on cherries, peaches,

bananas, barley, oats, wheat, and

peanuts as well as the proposed

tolerances for tebuconazole on grapes at

5.0 ppm. The TMRC is obtained by
Federal Register / Vol. 62, No. 43 / Wednesday, March 5, 1997 / Notices 10049

using a model which multiplies the

tolerance level residue for each

commodity by consumption data which

estimate the amount of each commodity

and products derived from the

commodities that are eaten by the U.S.

population and various population

subgroups. In conducting this exposure

assessment, very conservative

assumptions — 100 percent of all

commodities will contain tebuconazole

residues, and those residues would be at

the level of the tolerance — which result

in a large overestimate of human

exposure. Thus, in making a safety

determination for these tolerances,

Bayer took into account this very

conservative exposure assessment.

2. Dietary (drinking water) exposure.

There is no Maximum Contaminant

Level established for residues of

tebuconazole. Bayer was advised by the

EPA’s Environmental Fate and Ground

Water Branch’s (EFGWB) May 26, 1993

memorandum for our application for

use on bananas and peanuts that all

environmental fate data requirements

for tebuconazole were satisfied. The

EFGWB had determined that

tebuconazole is resistant to most

degradative processes in the

environment, including hydrolysis,

photolysis in water and aerobic and

anaerobic metabolism. Only minor

degradation occurred in soil photolysis

studies. The photolytic half-life of

tebuconazole is 19 days. Laboratory and

field studies have shown that the

mobility of tebuconazole in soil is

minimal. Therefore, tebuconazole bears

no apparent risk to ground water under

most circumstances.

3. Non-dietary exposure. Although

current registrations and the proposed

use on grapes are limited to commercial

crop production, Bayer has submitted

an application to register tebuconazole

on turf. Bayer has conducted an

exposure study designed to measure the

upper bound acute exposure potential of

adults and children from contact with

tebuconazole treated turf. The

population considered to have the

greatest potential exposure from contact

with pesticide treated turf soon after

pesticides are applied are young

children. Margins of exposure of 1,518

to 8,561 for 10–year–old children and

1,364 to 7,527 for 5–year–old children

were estimated by comparing dermal

exposure doses to the tebuconazole noobservable effect level of 1,000 mg/kg/

day established in a subacute dermal

toxicity study in rabbits. The estimated

safe residue levels for tebuconazole on

treated turf for 10–year–old children

ranged from 4.8 to 27.3 micrograms per

square centimeter (μg/cm2) and for 5–

year–old children from 4.4 to 24.0 μg/

cm2. This compares with the average

tebuconazole transferable residue level

of 0.319 μg/cm2 present immediately

after the sprays have dried. These data

indicate that children can safely contact

tebuconazole-treated turf as soon after

application as the spray has dried.

D. Cumulative Effects

At this time, the EPA has not made a

determination that tebuconazole and

other substances that may have a

common mechanism of toxicity would

have cumulative effects. Therefore, for

this tolerance, only the potential risks of

tebuconazole in its aggregate exposure

are considered.

E. Safety Determination

1. U.S. population. Based on a

complete and reliable toxicity database,

the EPA has adopted an RfD value of

0.03 mg/kg/day. This RfD is based on a

1–year dog study with a NOEL of 2.96

mg/kg/day and an uncertainty factor of

100. Using the conservative exposure

assumptions described above, Bayer has

determined that aggregate dietary

exposure to tebuconazole from the

previously established and the proposed

tolerances will utilize 7.1 percent of the

RfD for the U.S. population (48 states)

and 29.5 percent of the RfD for the most

highly exposed population subgroup

(children 1 to 6 years old). There is

generally no concern for exposures

below 100 percent of the RfD because

the RfD represents the level at or below

which daily aggregate exposure over a

lifetime will not pose appreciable risks

to human health. Therefore, there is a

reasonable certainty that no harm will

result from aggregate exposure to

tebuconazole.

2. Infants and children. In assessing

the potential for additional sensitivity of

infants and children to residues of

tebuconazole, the data from

developmental studies in both the rat

and rabbit and a 2–generation

reproduction study in the rat should be

considered. The developmental toxicity

studies evaluate any potential adverse

effects on the developing animal

resulting from pesticide exposure of the

mother during prenatal development.

The reproduction study evaluates any

effects from exposure to the pesticide on

the reproductive capability of mating

animals through two generations, as

well as any observed systemic toxicity.

A developmental toxicity study in the

rat, a developmental toxicity study in

the rabbit, two developmental studies in

the mouse and a 2–generation rat

reproduction study have been

conducted with tebuconazole. Maternal

and developmental toxicity NOELs of 30

mg/kg/day were determined in the rat

and rabbit studies. An oral mouse

developmental toxicity study had

maternal and developmental toxicity

NOELs of 10 mg/kg/day while the

mouse dermal developmental study had

a maternal NOEL of 30 mg/kg/day and

a developmental toxicity NOEL of 1,000

mg/kg/day. The parental and

reproductive NOELs in the 2–generation

rat reproduction study were determined

to be 15 mg/kg/day (300 ppm). In all

cases, the reproductive and

developmental NOELs were greater than

or equal to the parental NOELs. Bayer

concludes that this indicates that

tebuconazole does not pose any

increased risk to infants or children.

FFDCA section 408 provides that EPA

may apply an additional safety factor for

infants and children in the case of

threshold effects to account for pre-and

post-natal effects and the completeness

of the toxicity database. Based on

current toxicological data requirements,

the toxicology database for tebuconazole

relative to pre-and post-natal effects is

complete. Further for tebuconazole, the

NOEL of 2.96 mg/kg/bw from the 1–year

dog study, which was used to calculate

the RfD, is already lower than the

NOELs from the developmental studies

in rats (30 mg/kg bw/day) and rabbits

(30 mg/kg bw/day) by a factor of 10

times. Since a 100–fold uncertainty

factor is already used to calculate the

RfD, Bayer surmises that an additional

uncertainty factor is not warranted and

that the RfD at 0.03 mg/kg/bw/day is

appropriate for assessing aggregate risk

to infants and children.

Using the conservative exposure

assumptions, Bayer has determined

from a chronic dietary analysis that the

percent of the RfD utilized by aggregate

exposure to residues of tebuconazole

ranges from 9.2 percent for children 7 to

12 years old up to 29.5 percent for

children 1 to 6 years old. EPA generally

has no concern for exposure below 100

percent of the RfD. Therefore, based on

the completeness and reliability of the

toxicity data and the conservative

exposure assessment, Bayer concludes

that there is a reasonable certainty that

no harm will result to infants and

children from aggregate exposure to the

residues of tebuconazole, including all

anticipated dietary exposure and all

other non-occupational exposures.

F. International Issues

No Codex Maximum Residue Level

(MRL) have been established for

residues of tebuconazole on any crops at

this time. A Codex MRL of 2.0 ppm for

residues of tebuconazole on grapes has

been proposed. There are no established

tolerances for tebuconazole in or on

grapes in Canada and Mexico.
10050 Federal Register / Vol. 62, No. 43 / Wednesday, March 5, 1997 / Notices

G. Mode of Action

Tebuconazole, the active ingredient of

Folicur 3.6 F is a sterol demethylation

inhibitor (DMI) fungicide. It is systemic

and shows activity against powdery

mildew and black rot infecting grapes.

Tebuconazole provides protective

activity by preventing completion of the

infection process by direct inhibition of

sterol synthesis. It is rapidly absorbed

by plants and translocated systemically

in the young growing tissues.

II. Public Record

EPA invites interested persons to

submit comments on this notice of

filing. Comments must bear a

notification indicating the docket

control number PF–705.

A record has been established for this

notice docket under docket control

number PF–705 (including any

comments and data submitted

electronically as described below). A

public version of this record, including

printed, paper versions of electronic

comments, which does not include any

information claimed as CBI, is available

for inspection from 8:30 a.m. to 4 p.m.,

Monday through Friday, excluding legal

holidays. The public record is located in

Room 1132 of the Public Response and

Program Resources Branch, Field

Operations Division (7506C), Office of

Pesticide Programs, Environmental

Protection Agency, Crystal Mall #2,

1921 Jefferson Davis Highway,

Arlington, VA.

Electronic comments can be sent

directly to EPA at:

opp-docket@epamail.epa.gov

Electronic comments must be

submitted as an ASCII file avoiding the

use of special characters and any form

of encryption. The official record for

this notice of filing, as well as the public

version, as described above will be kept

in paper form. Accordingly, EPA will

transfer all comments received

electronically into printed, paper form

as they are received and will place the

paper copies in the official rulemaking

record which will also include all

comments submitted directly in writing.

The official rulemaking record is the

paper record maintained at the address

in ADDRESSES at the beginning of this

document.

List of Subjects

Environmental protection,

Administrative practice and procedure,

Agricultural commodities, Pesticides

and pests, Reporting and recordkeeping.

Dated: February 19, 1997.

Stephen L. Johnson,

Director, Registration Division, Office of

Pesticide Programs.

[FR Doc. 97–5200 Filed 3–4–97; 8:45 am]

BILLING CODE 6560–50–F

[PF–579A; FRL–5587–1]

Novartis; Pesticide Petition Withdrawal

AGENCY: Environmental Protection

Agency (EPA).

ACTION: Notice of withdrawal of

pesticide petition.

SUMMARY: EPA is withdrawing a

pesticide petition from Novartis

(formerly known as Ciba-Geigy

Corporation) for the combined residues

of the insecticide cyromazine, (N

cyclopropyl-1,3,5-triazine-2,4,6-triamine

plus its major metabolite, melamine,

1,3,5-triazine-2,4-6-triamine) for use in

or on certain commodites.

FOR FURTHER INFORMATION CONTACT:

George T. LaRocca, Product Manager

(PM) 13, Registration Division, (7505C),

Office of Pesticide Programs,

Environmental Protection Agency, 401

M. St., SW., Washington, DC 20460.

Office location, telephone number and

e-mail address: Rm. 200, CM#2, 1921

Jefferson Davis Highway, Arlington, VA;

703–305–6100; e-mail:

larocca.george@epamail.epa.gov.

SUPPLEMENTARY INFORMATION: EPA in a

notice issued in the Federal Register of

August 18, 1993 (58 FR 43892),

announced that Novartis, P.O. Box

18300, Greensboro, NC 27419, had filed

a pesticide petition (PP) 6F3422

proposing to amend 40 CFR part

180.414 to establish tolerances for the

combined residues of the insecticide

cyromazine, (N cyclopropyl-1,3,5-

triazine-2,4,6-triamine plus its major

metabolite, melamine, 1,3,5-triazine-2,4-

6-triamine) for use in or on cabbage,

sweet potatoes, sugar beets (roots and

tops), and sorghum (grain, forage and

fodder). The tolerances were to cover

residues resulting from the planting of

these crops as rotational crops following

the harvest of cyromazine treated crops.

On August 26, 1996 Novartis notified

EPA that it requests that the petition be

withdrawn without prejudice to future

filing. The Agency has withdrawn the

subject pesticide petition.

List of Subjects

Environmental protection,

Administrative practice and procedure,

Agricultural Commodities, Pesticides

and pests, Reporting and recordkeeping

requirements.

Dated: February 17, 1997.

Stephen L. Johnson,

Director, Registration Division, Office of

Pesticide Programs.

[FR Doc. 97–4884 Filed 3–4–97; 8:45 am]

BILLING CODE 6560–50–F

[PF–700; FRL–5586–1]

Rhone-Poulenc Ag Company;

Pesticide Tolerance Petition Filing

AGENCY: Environmental Protection

Agency (EPA).

ACTION: Notice of filing.

SUMMARY: This notice announces the

filing of a pesticide petition proposing

to establish tolerances for residues of

thiodicarb and its metabolite in or on

leafy vegetables, broccoli, cabbage and

cauliflower. The notice includes a

summary of the petition prepared by the

petitioner, Rhone-Poulenc Ag Company.

DATES: Comments, identified by the

docket control number [PF–700], must

be received on or before, April 4, 1997.

ADDRESSES: By mail, submit written

comments to: Public Response and

Program Resources Branch, Field

Operations Division (7506C), Office of

Pesticide Programs, Environmental

Protection Agency, 401 M St. SW.,

Washington, DC 20460. In person, bring

comments to: Rm. 1132, Crystal Mall #2,

1921 Jefferson Davis Highway,

Arlington, VA 22202.

Comments and data may also be

submitted electronically by sending

electronic mail (e-mail) to: oppdocket@epamail.epa.gov. Electronic

comments must be submitted either as

an ASCII file avoiding the use of special

characters and any form of encryption.

Comments and data will also be acceped

on disks in Wordperfect in 5.1 file

format or ASCII file format. All

comments and data in electronic form

must be identified by the docket control

number [PF–700]. Electronic comments

on this notice may be filed online at

many Federal Depository Libraries.

Additional information on electronic

submissions can be found below this

document.

Information submitted as a comment

concerning this notice may be claimed

confidential by marking any part or all

of that information as ‘‘Confidential

Business Information’’ (CBI).

Information so marked will not be

disclosed except in accordance with

procedures set forth in 40 CFR Part 2.

No CBI should be submitted through email. A copy of the comment that does

not contain CBI must be submitted for

inclusion in the public record.